Citi analyst Samantha Semenkow maintains $BioAge Labs (BIOA.US)$ with a buy rating, and maintains the target price at $45.
According to TipRanks data, the analyst has a success rate of 38.8% and a total average return of -8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs, a clinical-stage biotech specializing in therapies for metabolic diseases, has captured the attention due to its lead asset, azelaprag, which is an oral, small molecule agonist of the apelin receptor being developed to target obesity. The company's prospects are seen positively in light of the upcoming STRIDES readout, bolstered by azelaprag's oral administration, ease of manufacture, and strong preclinical data that suggest a promising clinical profile for treating obesity.
Initial findings indicate that BioAge Labs' azelaprag has shown promise, potentially enhancing weight loss when used alongside GLP-1s, and may also contribute to improved body composition and the quality of weight loss. Early data suggest that azelaprag not only contributes to weight reduction but also has a positive impact on muscle.
BioAge Labs, a clinical stage biotech specializing in metabolic diseases, is noted for its leading drug Azelaprag, which has a unique mechanism that mimics exercise, targeting obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析師Samantha Semenkow維持$BioAge Labs (BIOA.US)$買入評級，維持目標價45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.8%，總平均回報率為-8.2%。
此外，綜合報道，$BioAge Labs (BIOA.US)$近期主要分析師觀點如下：
BioAge Labs是一家專門研究代謝性疾病療法的臨床階段生物技術公司，由於其主要資產azelaprag而引起了人們的關注，阿澤拉普拉格是一種口服小分子阿佩林受體的激動劑，正在開發用於治療肥胖。鑑於即將發佈的STRIDES報告，該公司的前景樂觀，這得益於azelaprag的口服給藥、易於製造以及強有力的臨床前數據，這些數據表明治療肥胖的臨床前景令人鼓舞。
初步發現表明，BioAge Labs的azelaprag已顯示出前景，與GLP-1一起使用可能會增強減肥效果，還可能有助於改善身體成分和減肥質量。早期的數據表明，azelaprag不僅有助於減肥，而且對肌肉有積極影響。
BioAge Labs是一家專門研究代謝疾病的臨床階段生物技術公司，以其領先的藥物Azelaprag而聞名，該藥物具有模仿運動的獨特機制，可靶向肥胖。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
